化合物的选择性压力塑造了与治疗相关的骨髓瘤瘤的演变
Eline J M Bertrums1,2,3, Jurrian K de Kanter1,2, Lucca L M Derks1,2
1Princess Máxima Centrum for pediatric oncology, Utrecht, the Netherlands.
Nature communications
|July 17, 2024
概括
儿童的与治疗相关的髓状瘤 (t-MN) 在治疗后扩大,受生殖系TP53突变的影响. 这一发现有助于制定个性化癌症后续策略.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 血液学 血液学 血液学
背景情况:
- 与治疗相关的髓状瘤 (t-MN) 是癌症治疗的并发症,如化疗和放射治疗.
- 成人和儿童癌症幸存者的t-MN发育机制不同.
- 早期化疗对白血病发生的影响尚不清楚.
研究的目的:
- 在儿童癌症幸存者中调查t-MN的细胞起源和扩张动态.
- 探索生殖系遗传异常,特别是TP53突变在治疗诱导的白血病发生中的作用.
- 了解治疗暴露和t-MN发育中的遗传倾向之间的相互作用.
主要方法:
- 用单细胞全基因组测序来分析瘤异质性.
- 遗传学推断被用来重建t-MN克隆的进化历史.
- 对患有和没有Li-Fraumeni综合征的儿科患者进行了比较分析.
主要成果:
- 儿童的t-MN的创始细胞在停止治疗后开始扩张.
- 在Li-Fraumeni综合征患者 (有生殖系TP53突变) 中,在治疗期间发生t-MN扩张.
- 诱导的生长抑制似乎取决于TP53状态.
结论:
- 生殖系遗传变异,如TP53突变,与治疗暴露相互作用,诱导t-MN.
- 了解这些相互作用对于制定有针对性的,针对患者的治疗和后续计划至关重要.
- 这项研究揭示了与治疗相关的白血病发生的年龄相关机制.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K


